Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LLFP revoked:
https://www.sec.gov/litigation/admin/2016/34-78810.pdf
LLFP SEC Suspension for Financials / Filings delinquencies:
https://www.sec.gov/litigation/suspensions/2016/34-78506.pdf
Order:
https://www.sec.gov/litigation/suspensions/2016/34-78506-o.pdf
Admin Proceeding:
https://www.sec.gov/litigation/admin/2016/34-78507.pdf
TY RnR. Much appreciated.
Thx richboy. Was outta town. Only been back at the cave about 1 hour. Gotta read the 8k and see wth is going on. maybe make a call.
8-k out.. A/S increased to 500M. R/S effective Nov 5th.
500-1 R/S will do that
that was a quick drop
Delaware filings for the name change. Might shed some more light things.
i see some presentations are up coming. what about the filings you plan on posting?
Looks like this is our company: Zone Plates Ltd a London Based Nano-Tech company.
Looks like they are changing their website too.
http://www.google.com/url?sa=t&source=web&cd=1&ved=0CBYQFjAA&url=http%3A%2F%2Fwww.zoneplates.com%2F&ei=crDFTNHiNMOinQfEuLCBCg&usg=AFQjCNHdBqB3M5RApjJzlHnez-x23dHAsA
http://www.networksolutions.com/whois-search/nanodimensions.com
nanodimensions.com
Is this your domain name? Renew it now.
Thumbnail of nanodimensions.com
Current Registrar: EASYSPACE LTD.
IP Address: 62.233.121.5 (ARIN & RIPE IP search)
Record Type: Domain Name
Server Type: Zeus 4
Lock Status: clientTransferProhibited
WebSite Status: Active
Registrant:
Zone Plates Ltd
8 South Way
London, N9 0AB
GB
Domain name: NANODIMENSIONS.COM
Administrative Contact:
CHARALAMBOUS, PAMBOS pambos@zoneplates.com
8 South Way
London, N9 0AB
GB
0207 887 6921 Fax: 0207 887 6921
Technical Contact:
CHARALAMBOUS, PAMBOS pambos@zoneplates.com
8 South Way
London, N9 0AB
GB
0207 887 6921 Fax: 0207 887 6921
i still watching and kinda regretting not pulling trigger at 0056
Nice chart for CTHP my good friend. TY for bringing it by. News has been non-exitent of late however they have their filings up to date, not really skipping a beat, so make sure at a minimum you watch her.
Well they just filed a 10q this month and it states 85 mil and change O/S and looking at recent filings that hasn't increased in over a year or more. The float as I stated from the EF fundamentals was approx 4.5 mil, and I can't say that is correct but seems to move like it is that. With a 52 week low of .004 and a 52 week high which according to Pink Sheets now is .14 and the co. staying current in filings, no increase to O/S, recent kick butt volume, I feel pretty good. You?
i actually called the TA for share structure and they had to refer me to thre company and when they didnt have there phone number, they gave me the attorneys number in which i called and got hold of secratary and she transfered me to so and so,but even though he was in..it sent me to voice mail.i left message but never heard nothing back.this was when it ran to a penny back in august.
did you buy some yesterday?
"IF" there was a catalyst of sorts to light this Pup, she couldn't be slowed down, imo of course.
i was watching when it went to a penny real fast and than quit and dropped,but the ask was always too high,1st time i saw the ask below 0075 was this week.
Last 3 days have been above avg 10 day volume.
2010/10/22 0.0060 0.0076 0.0050 0.0075 537,300 0.0075
2010/10/21 0.0060 0.0073 0.0055 0.0056 800,000 0.0056
2010/10/20 0.0070 0.0073 0.0070 0.0070 287,700 0.0070
Today she demonstrated what can happen with a little positive volume as well. Up 33.93% on just a tad over half a million shares.
Still a fully reporting OTCBQ company with 85 Mil O/S and according to my fundamentals link from Equity Feed a 4.54 Mil float with a market cap of 633.21K. Not really sure what the deal is but have had her on watch for over a month. Chart is shaping up and we are not far off of the 52 week low and have a very long way to get to the 52 week high.
http://stockcharts.com/h-sc/ui?s=CTHP&p=D&b=5&g=0&id=p78537898929
Following the volume and $$$ here. Like I said last night. Don't really care if they sell whigets, weld wire racks or refurbish CD players. She's Flinchin and she's Flinchin nicely! Can't wait till she gets noticed. ;)
Bollinger Bands has closed below upper band by 10.3%; above bottom band by 89.7%; Bollinger Bands are 74.9% narrower than normal.The narrow width of the bands suggests low volatility as compared to CTHP.OB's normal range. The bands have been in this narrow range for 85 bars. This is often a sign that a market may be about to initiate a new trend.
http://www.allotcbb.com/quote.php?symbol=cthp
only have this on watch,almost got in yesterday when the spread narrowed some.was out most of today.what are you thinking on this one?
Another solid volume day my friend. 3.38 times the avg 10 day
Hey buddy, doesn't seem to be dodgin you here.
Apt post! Some solid made points S.H. I'm liking the way things are looking here.
trying to make a buck somewhere.it keeps dodging me.lol
Personally I don't give a rats Azz if they are just now ordering wire racks to display their product at the end of grocery store isles but I would prefer they had a cure for cancer. Shells have stories. Maybe this one has one coming? It's still a fully reporting OTCBQ company and according to this...
As of September 7, 2010, the Company had outstanding 85,541,266 shares of common stock, par value $0.001 per share.
My fundamentals link from Equity Feed lists 85.7 mil O/S so in line with above, and a 4.54 Mil float with a 52 week high of .27 and a 52 week low of .004.
They are spending money to report and keep this current all the while not dumping.
Also as of the last 10q this...
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. As of October 13, 2010, the Company had outstanding 85,569,477 shares of common stock, par value $0.001per share.
So doesn't appear anyone dumping on our parade does it.
Personally I think we got someone by the short hairs.
What I do care about is this had 15.5 times the avg 10 day volume today and the last 330,000 were bought at the ask, some were mine and several went off above that as well.
Volume precedes price. Play or don't but somebody is and I'm not gonna miss it.
Some Volume?!?!? 15.5 times the avg 10 day. How ya doin RnR my friend?
some vol today and the spread is alot closer together 005 x 0056
This is just a shell... with no interest what so ever.. this guy.. Chene... he has never answered his phone in the last 100 times I have tried to call him in regards to restarting the company. About the only way this shell will ever amount to something is for someone to petition the court for custodianship over the company, declaring Chene as incompetent,so the court will award custodianship to someone else who would attempt to restart the company... the company has a great name... but.. those people behind it.. are questionable..
Titon
Still watching. Avg 10 day volume 10,999. Today 7.5 times the avg. OTCQB co. Last 10k filed states 85 Mil O/S, float dunno. If she starts to go, gonna get her before she gets moving.
Avg 10 Day volume 38,613, yesterday 265,167 or now 6.86 times the 10 day avg and a little pop of 32% on that volume.
As of the 10K filed 14 Sept...
As of September 7, 2010, the Company had outstanding 85,541,266 shares of common stock, par value $0.001 per share.
My fundamentals link from Equity Feed lists 85.7 mil O/S so in line with above, and a 4.54 Mil float with a 52 week high of .27 and a 52 week low of .004.
Watchin you. 10 day avg volume 33,380, today 153,200. 4.58 times.
Hmmmm, They did file the 10k Today A/Hs.
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. As of September 7, 2010, the Company had outstanding 85,541,266 shares of common stock, par value $0.001 per share.
oh wow! yep, i had beautiful timing on that lil run,just b4 the big dump.was asking about L2's i believe?
so...how you been doin'!
I think EYSM, if I remember correctly.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
324
|
Created
|
06/09/09
|
Type
|
Free
|
Moderators |
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
CTI’s first investment under this strategy is NanoTherapies LLC. Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells. The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.
The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Four drugs have been identified for accelerated market delivery and early revenue: Methotrexate, Cytarabine, Fludarabine and Daunorubicin. Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
CTI’s first investment under this strategy is NanoTherapies LLC. Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells. The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.
The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Four drugs have been identified for accelerated market delivery and early revenue: Methotrexate, Cytarabine, Fludarabine and Daunorubicin. Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.
Cancer Therapeutics will be in a position to engage high level personnel and intellectual capital from NanoTherapies to evaluate other synergistic investment opportunities. CTI will then pursue the most promising and valuable technologies to reach the market expeditiously and benefit the lives of cancer patients worldwide.
Cancer Therapeutics Inc is a Delaware corporation. CTI’s Common Stock is listed on the NASD Electronic Bulletin Board under the symbol “CTHP.” The Company’s stock has been traded on the Bulletin Board since March, 2007.
Cancer Therapeutics Inc is located in South Jordan (Salt Lake City), Utah.
Cancer Therapeutics Inc
10757 S. River Front Pkwy.
Suite 125
South Jordan, Utah 84095
Telephone (801) 816-2533
Facsimile (801) 816-2599
Email
Chene Gardner
President, Chief Executive Officer, Chief Financial Officer
John D. Thomas
General Counsel
Outstanding Shares: 85,541,266 as of Sep 07, 2010
The information contained within this iBox including web links, copied information, and any other associated messages/media (hereinafter collectively referred to as "Information") is provided for informational purposes only. The Information should not be construed as investment/trading advice and is not meant to be a solicitation or recommendation to buy, sell, or hold Cancer Therapeutics, Inc. (CTHP) stock.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |